

Diabetic Retinopathy (DR)



**Help change the way
your eyes see the world**

Diabetic Retinopathy (DR)


may try to slow your eyes down.
EYLEA may be able to help.



SELECT IMPORTANT SAFETY INFORMATION

EYLEA is a prescription medicine administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.




WHAT IS DIABETIC RETINOPATHY?

DR happens when too much blood sugar (glucose) damages the blood vessels in the retina. DR is the most common eye problem caused by diabetes and can lead to vision loss.

Who does DR affect?

Diabetes is the leading cause of new cases of blindness in people 20 to 74 years of age in the United States. DR is the most common diabetic eye disease and can lead to vision loss—**but early detection, timely treatment, and appropriate follow-up care may reduce the severity of the disease.**



Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

How can Diabetic Retinopathy affect my eyes?

- The retina in the back of the eye does not get enough oxygen and nutrients
- Blood vessels in the eye can become swollen and blocked
- Blood vessels can leak blood into the retina

DR can get worse over time

Throughout the early stages of DR, there may be no visual symptoms.

In the moderate stages, the bleeding continues and visual symptoms may begin to appear, such as blurriness or floating spots in your vision (floaters).

If DR progresses into its most advanced stage (proliferative), an increased growth of new blood vessels occurs. These new blood vessels are fragile and easily damaged—which adds to the swelling and leaking.

SELECT IMPORTANT SAFETY INFORMATION

Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.



Learn more
at [EYLEA.com](https://www.eylea.com)

 **EYLEA[®]**
(aflibercept) Injection
For Intravitreal Injection

EYLEA may be able to help improve your Diabetic Retinopathy

**EYLEA has been studied in more than 3,000 people
with certain diseases of the retina.**

Early detection, timely treatment, and appropriate follow-up care may reverse the severity of the disease.

EYLEA is a prescription medicine given by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.

A clinical study of 402 people with moderately severe to severe nonproliferative DR (NPDR) evaluated EYLEA in patients who had DR without Diabetic Macular Edema (DME). Patients received two different dosing schedules of EYLEA and were compared to patients who did not receive EYLEA treatment (control group).

Your individual results may vary. Discuss with your eye care team what treatment schedule with EYLEA may be right for you.

SELECT IMPORTANT SAFETY INFORMATION

In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.



EYLEA helped Diabetic Retinopathy patients without DME reduce DR severity.

- At 6 months of treatment, **58% of EYLEA patients improved compared to 6% in the control group**
- At 1 year of treatment, **80% of EYLEA patients* improved compared to 15% in the control group**

*Patients received EYLEA every 2 months after 5 monthly doses.

Improvement was defined as at least a 2-step improvement on the DR Severity Scale from baseline.

The image below is an example of a 2-step improvement from Severe DR to Moderate DR:



SELECT IMPORTANT SAFETY INFORMATION

There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.

Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.




EYLEA helped Diabetic Retinopathy patients with DME improve their vision.

- In 2 clinical studies, 862 people with DR and DME received injections of EYLEA (2 mg) either once every 8 weeks after 5 initial monthly doses or once every 4 weeks or laser treatment
- On average, people treated with EYLEA in the studies gained about 10 more letters on the eye chart at 1 year, which continued through 2 years with treatment

In Diabetic Retinopathy patients with DME, disease improvement was measured as at least a 2-step improvement on the DR Severity Scale from baseline.

- After 2 years, the severity of DR was reduced in some patients with EYLEA

These results are from clinical studies; your individual results may vary. Discuss with your eye care team what treatment schedule with EYLEA may be right for you.



**Ask your eye doctor if EYLEA is right for you.
Visit [EYLEA.com](https://www.eylea.com) to learn more.**

IMPORTANT SAFETY INFORMATION AND INDICATIONS

- EYLEA is a prescription medicine administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
- Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
- In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
- There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
- Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
- The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, vitreous floaters, moving spots in the field of vision, and increased pressure in the eye.

- It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.
- EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is a prescription medicine approved for the treatment of patients with Wet Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).



Help your eyes fight back

Financial Support

EYLEA has several programs available—depending on your insurance situation—to help eligible patients with the cost of EYLEA.

Either you or someone from your eye doctor's office can call 1-855-EYLEA4U (1-855-395-3248) Monday through Friday 9 AM to 8 PM Eastern Time to get you started.

Sign up at **EYLEA.com** to get the latest materials and communications about EYLEA—and a complimentary pocket magnifier, too.



Your eyes are a beautiful pair.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

EYLEA and EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

REGENERON

 **EYLEA**[®]
(aflibercept) Injection
For Intravitreal Injection